{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:57:32Z","timestamp":1792616252333,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017804","name":"City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012210","name":"The Carol Moss Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jinf.2026.106855","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:55:53Z","timestamp":1789397753000},"page":"106855","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-8253","authenticated-orcid":false,"given":"Sandra","family":"Ortega-Francisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Prudente de Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Chiuppesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7725-1275","authenticated-orcid":false,"suffix":"Jr","given":"Miguel-Angel","family":"Gutierrez-Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5258-5720","authenticated-orcid":false,"given":"Corinna","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Kaltcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5366-9842","authenticated-orcid":false,"given":"Jada","family":"Mack-Onyeike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4910-0678","authenticated-orcid":false,"given":"Jacqueline","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4995-0450","authenticated-orcid":false,"given":"Katrin","family":"Tiemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Grifoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7013-2250","authenticated-orcid":false,"given":"Alessandro","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasima","family":"Rida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wussow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McKee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5574-3051","authenticated-orcid":false,"given":"Erica","family":"Raiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0109-5991","authenticated-orcid":false,"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3579-7083","authenticated-orcid":false,"given":"Don J.","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jinf.2026.106855_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwaf138","article-title":"SARS-CoV-2 keeps evolving, so must our research efforts","volume":"12","author":"Ma","year":"2025","journal-title":"Natl Sci Rev"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41541-025-01348-x","article-title":"Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies","volume":"11","author":"Te Marvelde","year":"2026","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.jinf.2026.106855_bib3","doi-asserted-by":"crossref","DOI":"10.1071\/MA20013","article-title":"COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't","author":"Mackenzie","year":"2020","journal-title":"Microbiol Aust"},{"issue":"2","key":"10.1016\/j.jinf.2026.106855_bib4","article-title":"Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4\/5 Bivalent Booster","volume":"12","author":"Machado","year":"2024","journal-title":"Vaccin (Basel)"},{"issue":"2","key":"10.1016\/j.jinf.2026.106855_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chom.2023.11.010","article-title":"Pre-existing SARS-2-specific T cells are predicted to cross-recognize BA.2.86","volume":"32","author":"Sette","year":"2024","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.jinf.2026.106855_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104745","article-title":"Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants","volume":"25","author":"Chiuppesi","year":"2022","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.jinf.2026.106855_bib8","article-title":"Evolving SARS-CoV-2 vaccines: from current solutions to broad-spectrum protection","volume":"13","author":"Qiao","year":"2025","journal-title":"Vaccin (Basel)"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"La Rosa","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jinf.2026.106855_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142802","article-title":"Correction: a multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1473-3099(21)00128-6","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial","volume":"22","author":"Afolabi","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib12","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-022-00436-6","article-title":"Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates","volume":"7","author":"Chiuppesi","year":"2022","journal-title":"NPJ Vaccin"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-023-00640-y","article-title":"Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants","volume":"8","author":"Wussow","year":"2023","journal-title":"NPJ Vaccin"},{"issue":"4","key":"10.1016\/j.jinf.2026.106855_bib15","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2666-5247(22)00027-1","article-title":"Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial","volume":"3","author":"Chiuppesi","year":"2022","journal-title":"Lancet Microbe"},{"issue":"9","key":"10.1016\/j.jinf.2026.106855_bib16","article-title":"Stimulation of potent humoral and cellular immunity via synthetic dual-antigen MVA-Based COVID-19 vaccine COH04S1 in cancer patients post hematopoietic cell transplantation and cellular therapy","volume":"11","author":"Chiuppesi","year":"2023","journal-title":"Vaccin (Basel)"},{"issue":"7","key":"10.1016\/j.jinf.2026.106855_bib17","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.jinf.2026.106855_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.70268","article-title":"Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine","volume":"208","author":"Ortega-Francisco","year":"2026","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jinf.2026.106855_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.jinf.2026.106855_bib20","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1016\/j.vaccine.2024.03.030","article-title":"COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study","volume":"42","author":"Morgan","year":"2024","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.jinf.2026.106855_bib21","article-title":"Reactogenicity differences between adjuvanted, protein-based and Messenger Ribonucleic Acid (mRNA)-based COVID-19 vaccines","volume":"12","author":"Rousculp","year":"2024","journal-title":"Vaccin (Basel)"},{"issue":"10318","key":"10.1016\/j.jinf.2026.106855_bib22","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jinf.2026.106855_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010870","article-title":"Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses","volume":"19","author":"Wang","year":"2023","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.jinf.2026.106855_bib24","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"8047","key":"10.1016\/j.jinf.2026.106855_bib25","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2025","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib26","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41467-024-46490-7","article-title":"Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86\/JN.1 lineages combining increased fitness and antibody evasion","volume":"15","author":"Planas","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.jinf.2026.106855_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054371","article-title":"Can T cells abort SARS-CoV-2 and other viral infections?","volume":"24","author":"Swadling","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.jinf.2026.106855_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","article-title":"search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms","volume":"21","author":"Cankat","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"24","key":"10.1016\/j.jinf.2026.106855_bib29","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jinf.2026.106855_bib30","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1038\/s41467-023-38020-8","article-title":"Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion","volume":"14","author":"Eser","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jinf.2026.106855_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110138","article-title":"Evolution of protective SARS-CoV-2-specific B and T cell responses upon vaccination and Omicron breakthrough infection","volume":"27","author":"Ahmed","year":"2024","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.jinf.2026.106855_bib32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445326001817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:28:17Z","timestamp":1792614497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445326001817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0163445326001817"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106855","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2026.106855","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106855"}}